Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BCD-250 Vaccine for COVID-19
NCT05037188Phase 2Terminated
- Sponsor
- BIOCAD
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BCD-250 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by BIOCAD. Primary endpoint: Percentage of subjects with ≥ 4 fold rise of serum SARS-CoV-2-specific IgG titer from baseline at Day 56. Started Aug 2021; status: terminated.
02
Drugs
BCD-250
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05037188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037188.